Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection

The multidrug-resistant (MDR) human immunodeficiency virus 1 (HIV-1) infection is an unmet medical need. HIV-1 capsid plays an important role at different stages of the HIV-1 replication cycle and is an attractive drug target for developing therapies against MDR HIV-1 infection. Lenacapavir (LEN) is...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Tafadzwa Dzinamarira, Mazen Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A. Rabaan, Amal H. Alfaraj, Bashayer M. AlShehail, Nouf Alotaibi, Shams M. AlShehail, Mohd Imran
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2023-05-01
Rangatū:	Medicina
Ngā marau:	Lenacapavir Sunlenca GS-6207 HIV-1 capsid patent prospects
Urunga tuihono:	https://www.mdpi.com/1648-9144/59/6/1041
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!